Morgan Stanley’s Vaxcyte PCVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$42.8M Sell
735,907
-99,480
-12% -$5.4M ﹤0.01% 2264
2025
Q4
$38.5M Buy
835,387
+50,904
+6% +$2.28M ﹤0.01% 2339
2025
Q3
$28.3M Sell
784,483
-57,439
-7% -$1.9M ﹤0.01% 2556
2025
Q2
$27.4M Buy
841,922
+234,971
+39% +$7.7M ﹤0.01% 2495
2025
Q1
$22.9M Sell
606,951
-86,382
-12% -$6.91M ﹤0.01% 2554
2024
Q4
$56.8M Sell
693,333
-1,536
-0.2% -$153K ﹤0.01% 1727
2024
Q3
$79.4M Buy
694,869
+285,177
+70% +$25.7M 0.01% 1415
2024
Q2
$30.9M Sell
409,692
-80,762
-16% -$5.5M ﹤0.01% 2197
2024
Q1
$33.5M Sell
490,454
-584,276
-54% -$40.5M ﹤0.01% 2140
2023
Q4
$67.5M Buy
1,074,730
+665,180
+162% +$34.5M ﹤0.01% 2132
2023
Q3
$20.9M Sell
409,550
-15,540
-4% -$767K ﹤0.01% 2410
2023
Q2
$21.2M Buy
425,090
+254,467
+149% +$12.1M ﹤0.01% 2415
2023
Q1
$6.39M Buy
170,623
+2,508
+1% +$106K ﹤0.01% 3563
2022
Q4
$8.06M Buy
168,115
+125,582
+295% +$4.93M ﹤0.01% 3283
2022
Q3
$1.02M Sell
42,533
-95,138
-69% -$2.41M ﹤0.01% 4865
2022
Q2
$3M Buy
137,671
+48,740
+55% +$1.13M ﹤0.01% 4212
2022
Q1
$2.15M Buy
88,931
+31,088
+54% +$679K ﹤0.01% 4470
2021
Q4
$1.38M Buy
57,843
+19,767
+52% +$460K ﹤0.01% 4857
2021
Q3
$966K Buy
38,076
+18,200
+92% +$441K ﹤0.01% 5063
2021
Q2
$449K Buy
19,876
+10,405
+110% +$213K ﹤0.01% 5595
2021
Q1
$187K Sell
9,471
-4,088
-30% -$103K ﹤0.01% 5693
2020
Q4
$360K Buy
13,559
+10,600
+358% +$394K ﹤0.01% 5263
2020
Q3
$146K Buy
2,959
+2,859
+2,859% +$114K ﹤0.01% 5259
2020
Q2
$3K Buy
+100
New +$3.22K ﹤0.01% 6399

Other funds holding PCVX